Atara Biotherapeutics, Inc.
ATRA
$9.81
$1.0311.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.60M | 3.45M | 17.58M | 98.15M | 32.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.60M | 3.45M | 17.58M | 98.15M | 32.75M |
| Cost of Revenue | 783.00K | 3.03M | 554.00K | 39.52M | 22.05M |
| Gross Profit | 812.00K | 428.00K | 17.02M | 58.63M | 10.70M |
| SG&A Expenses | 3.37M | 3.98M | 5.94M | 10.01M | 9.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.01M | 7.00M | 12.86M | 49.53M | 44.96M |
| Operating Income | -5.42M | -3.55M | 4.72M | 48.62M | -12.20M |
| Income Before Tax | -3.41M | -4.28M | 2.39M | 38.01M | -12.71M |
| Income Tax Expenses | 0.00 | 28.00K | 3.00K | -- | -19.00K |
| Earnings from Continuing Operations | -3.41M | -4.30M | 2.39M | 38.01M | -12.69M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.41M | -4.30M | 2.39M | 38.01M | -12.69M |
| EBIT | -5.42M | -3.55M | 4.72M | 48.62M | -12.20M |
| EBITDA | -4.37M | -3.19M | 5.62M | 50.41M | -11.10M |
| EPS Basic | -0.25 | -0.32 | 0.20 | 3.53 | -1.19 |
| Normalized Basic EPS | -0.29 | -0.20 | 0.20 | 2.78 | -0.74 |
| EPS Diluted | -0.25 | -0.32 | 0.19 | 3.50 | -1.19 |
| Normalized Diluted EPS | -0.29 | -0.20 | 0.20 | 2.75 | -0.74 |
| Average Basic Shares Outstanding | 13.62M | 13.56M | 12.20M | 10.76M | 10.71M |
| Average Diluted Shares Outstanding | 13.62M | 13.56M | 12.31M | 10.85M | 10.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |